Navigation Links
Reshaping pharmaceutical quality
Date:6/2/2008

The first scientific papers outlining the progress made on the Product Quality Lifecycle Implementation (PQLI) initiative are being published in the June 2008 issue of the Journal of Pharmaceutical Innovation (JPI). Written by experts representing the global pharmaceutical manufacturing industry, these papers present practical scientific and technological approaches to implementing ICH* documents that address pharmaceutical development, quality risk management and pharmaceutical quality systems. The June issue will be published in print and is available free of charge on Springer's electronic information platform SpringerLink at http://www.springerlink.com/content/1939-8042 with the possibility to comment.

The PQLI initiative was launched by the International Society for Pharmaceutical Engineering (ISPE) in June 2007 to help industry find practical technical solutions to the challenges of implementing guidelines put forth by the ICH. The first three task teams formed focused on criticality, design space and control strategy, and how these areas are linked; a Legacy Products Task Team has also been formed as the fourth topical area. PQLI is projected to be at least a five-year initiative that has started with interactive fact-gathering sessions held in the USA and Europe. For background information on the PQLI papers, please see http://springer.com/12247.

The criticality study describes a mechanism for categorizing and delineating criticality for quality attributes, variables, material attributes and process parameters in accordance with a risk-based approach reflective of quality by design (QbD) principles. Design space discussions considered the linkage of the patient experience with product quality. The Control Strategy Team has proposed a model process to enable a clear logic to be used on how a control strategy differentiates between
'/>"/>

Contact: Joan Robinson
joan.robinson@springer.com
49-622-148-78130
Springer
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
2. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
3. Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence
4. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
5. KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings
6. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
7. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
8. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
9. FDLI Publishes Comprehensive Handbook on Pharmaceutical Risk Management
10. Research Study Shows That Pharmaceutical Field Sales Reps Productivity Inhibited by Unnecessary Internal Communication
11. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... J. O,Shea, M.D., scientific director at the National Institute ... been named the 2014 recipient of the Ross Prize ... open-access journal Molecular Medicine . The award will ... Academy of Sciences in Manhattan, followed by scientific presentations ... part of the National Institutes of Health. , The ...
(Date:4/23/2014)... The American Society for Radiation Oncology (ASTRO) has ... Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based ... therapy in the treatment of endometrial cancer. The ... 2014 issue of Practical Radiation Oncology ... The full-length guideline is available as an open-access ...
(Date:4/23/2014)... Ind. - Purdue University researchers have developed a way ... cell by using tiny gold particles with tails of ... of agricultural and biological engineering, used gold nanoparticles to ... as BRCA1 messenger RNA splice variants, which can indicate ... of these mRNA splice variants in a cell can ...
(Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
(Date:4/23/2014)... 2014Men whose testosterone falls below normal levels are more ... and have heart disease and type 2 diabetes. A ... for further testing and possible treatment is described in ... a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. ... of Men,s Health website at http://www.liebertpub.com/jmh . ...
Breaking Medicine News(10 mins):Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2
... A leading authority on the aging, health and retirement of ... the ability of Americans to provide for the long term ... November 12, Dr. Dychtwald will address members of the news ... importance of long term care planning. This topic is ...
... , PHILADELPHIA, Oct. 28 Health Partners announced ... the state Children,s Health Insurance Program (CHIP). CHIP, brought ... already begun enrolling members in Philadelphia County and will ... , CHIP offers quality health insurance to all uninsured ...
... Oct. 28 Carefx Corporation , ... and safety of patient care, is listed among the " ... by IDC, a leading IT market research and advisory firm. ... Oct. 26, profiles companies "with the vision and technology to have ...
... a subsidiary of Eisai Inc., announced today that it ... Biotech Inc. for development and commercialization of an antibody ... tumors. , Under the terms of the ... for the development, manufacture and sale of the antibody. ...
... Health Foundation today announced that it has awarded The ... to create education and outreach programs that empower pharmacists, ... misuse in their communities. , According to the Ohio ... Ohio high school students have reported using a prescription ...
... LONDON, October 28 Even though no-one wants to ... to look good at the,ubiquitous Christmas Party then follow the realbuzz.com guide ... diet and healthy living go out,the window, so now,s the time to ... - we wouldn,t be realbuzz.com if we didn,t offer this piece of,advice ...
Cached Medicine News:Health News:Dr. Ken Dychtwald to Discuss Looming 'Caregiver Crunch' and the Importance of Proactive Long Term Care Planning 2Health News:Health Partners to Offer Health Insurance Through the Children's Health Insurance Program 2Health News:Carefx Named an Innovative Information Access 'Company to Watch' By Leading Market Research Firm 2Health News:Carefx Named an Innovative Information Access 'Company to Watch' By Leading Market Research Firm 3Health News:Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody 2Health News:Cardinal Health Foundation, The Ohio State University College of Pharmacy Join Forces to Prevent Prescription Medication Abuse 2Health News:The Countdown to Christmas - The realbuzz.com Guide to a Healthier You! 2
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of ... Home Medical Equipment, Inc. ("Progressive") of Clarion, PA ... acquisition were not disclosed. Progressive is a ... range of sleep, mobility, and respiratory products to customers in ...
(Date:1/14/2014)... Jan. 14, 2014 NineSigma , Inc., the ... Innovation Leadership Summit , May 14-16, 2014 at ... Cleveland Ohio . This is ... committed to breakthrough achievements through open innovation. Participants will ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... financial results for the first quarter ended March 31, 2011 ... financial markets. NxStage will also host a conference ... 2011 to discuss its first quarter financial results. To listen ...
... Novartis Pharmaceuticals Corporation ("Novartis") announced today that the ... Advisory Committee (ODAC) recommended approval of Afinitor® (everolimus) ... neuroendocrine tumors (NET) of pancreatic origin. ... from the everolimus RADIANT (RAD001 In Advanced Neuroendocrine ...
Cached Medicine Technology:NxStage® to Report First Quarter Fiscal 2011 Financial Results 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10
... a vacuum tube for the collection, transport ... immunophenotyping by flow cytometry. The preservative contained ... the white blood cell cluster of differentiation ... Patient samples collected in Cyto-Chex BCT are ...
Streck-ONYX-Pack is specially designed for use on Coulter® ONYX Series instruments. Each pack contains diluent and lysing agent. The shelf life is one year from date of manufacture....
... reagent manufactured for the simultaneous quantitative ... cells. Streck-Lysing Agent IIIC is for ... S Plus II, III, IV, V, ... JT Series. The shelf life is ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Medicine Products: